Abstract
Objective To describe the sociodemographic characteristics associated with e-cigarette ever use and to examine the impact of e-cigarette ever use on lung function impairment in an ageing population. Design A cross-sectional analysis of data from the Canadian Longitudinal Study on Aging. Setting A national stratified sample of 44 817 adults living in Canadian provinces. Participants Respondents included participants aged 45-85 and residing in the community in Canadian provinces. Outcome measures The Global Lung Function Initiative normative values for forced expiratory volume in the first second (FEV 1), forced vital capacity (FVC), forced expiratory ratio (FEV 1 /FVC) appropriate for age, sex, height and ethnicity were used to interpret the severity of lung function impairment. Multinomial logistic regression analysis was used to examine the impact of e-cigarette ever use on obstructive and restrictive lung function impairment. Results The prevalence of e-cigarette ever use was 6.5% and varied by sociodemographic factors including higher prevalence among individuals younger than 65 years, those with lower education attainment and those with lower annual household income. E-cigarette ever use was associated with 2.10 (95% CI 1.57 to 2.08) times higher odds of obstructive lung function impairment after adjusting for conventional cigarette smoking and other covariates. Individuals with exposure to e-cigarette ever use and 15 or more pack-years had 7.43 (95% CI 5.30 to 10.38) times higher odds for obstructive lung function impairment when compared with non-smokers and non-e-cigarette users after adjusting for covariates. Smokers with 15 or more pack-years had higher odds of restrictive lung function impairment irrespective of e-cigarette ever use. Conclusions Ever use of e-cigarettes was found to be associated with obstructive lung function impairment after adjusting for covariates, suggesting that e-cigarette use may be adding to the respiratory and other chronic disease burden in the population.
| Original language | English |
|---|---|
| Article number | e051519 |
| Journal | BMJ Open |
| Volume | 11 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - Oct 27 2021 |
Bibliographical note
Funding Information:Funding This research was made possible using the data/biospecimens collected by the Canadian Longitudinal Study on Aging (CLSA). Funding for the Canadian Longitudinal Study on Aging (CLSA) is provided by the Government of Canada through the Canadian Institutes of Health Research (CIHR) under grant reference: LSA 94473 and the Canada Foundation for Innovation and provincial governments (Newfoundland, Nova Scotia, Quebec, Ontario, Manitoba, Alberta and British Columbia). This research has been conducted using the Baseline Tracking Dataset version 3.6, Comprehensive Dataset version 4.2, Follow-up 1 Tracking Dataset version 2.0, Comprehensive Dataset version 3.0, CLSA Sample Weights Version 1.2 under Application Number 1909036. The CLSA is led by Drs Parminder Raina, Christina Wolfson and Susan Kirkland. Parminder Raina holds the Raymond and Margaret Labarge Chair in Optimal Aging and Knowledge Application for Optimal Aging, is the Director of the McMaster Institute for Research on Aging and the Labarge Centre for Mobility in Aging and holds a Tier 1 Canada Research Chair in Geroscience.
Publisher Copyright:
© 2021 Georg Thieme Verlag. All rights reserved.
ASJC Scopus Subject Areas
- General Medicine
PubMed: MeSH publication types
- Journal Article
- Research Support, Non-U.S. Gov't